Disanto G, Sacco R, Bernasconi E, et al. - In this investigation, the humoral response to SARS-CoV-2 was appropriate when treated with cladribine and teriflunomide, but diminished/absent when treated with anti-CD20 treatments and sphingosine-1-phosphate receptor (S1P) modulators.

• Between February 25, 2021, and May 11, 2021, 120 patients were enrolled in the following treatment groups: anti-CD20 (n = 58: ocrelizumab = 32, rituximab = 25, ofatumumab = 1), sphingosine-1-phosphate receptor (S1P) modulators (n = 9: fingolimod = 7, ozanimod = 2), cladribine (n = 15), teriflunomide (n = 24), and no therapy (n = 14).

• Delaying anti-CD20 infusions for 3 to 6 months before vaccination, on the other hand, may increase the likelihood of producing effective humoral responses, particularly in clinically and radiologically stable patients.

• Six months following the last infusion, CD19 ⁺ B cells began to repopulate.

• SARS-CoV-2 IgG levels increased with time since the last anti-CD20 injection, as did the CD19 ⁺ B-cell count.

• When rituximab and ocrelizumab were studied separately, the associations were comparable.

• While waiting for vaccination, no patients experienced relapses.